Melanoma Stage IV Clinical Trial
Official title:
Beta Glucan's Effect on Pembrolizumab Immunologic Response in Stage III-IV Melanoma
The purpose of this study is to determine how beta-glucan affects the immune system in subjects with melanoma.
This is a clinical pilot study using oral beta-glucan on patients with advanced stage III-IV melanoma without evidence of disease receiving adjuvant Pembrolizumab. The aim is to see whether beta-glucan treatment in combination with Pembrolizumab may provide augmented immunologic phenotypes such as decreased peripheral MDSCs, enhanced T effector cell function, or enhanced cytokine production in the peripheral blood or plasm of enrolled subjects. Secondary outcome measures will include clinical endpoints such as recurrence, progression free survival and overall survival. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT04330430 -
Neo-adjuvant T-VEC + Nivolumab Combination Therapy for Resectable Early Metastatic (Stage IIIB/C/D-IV M1a) Melanoma With Injectable Disease
|
Phase 2 | |
| Withdrawn |
NCT04007588 -
A Phase II Trial of Neoadjuvant Treatment With PD-1 Inhibition (Nivolumab) With or Without IDO Inhibition (BMS-986205) and With or Without CTLA-4 Inhibition (Ipilimumab) in Resectable Stage III or IV Melanoma
|
Phase 2 | |
| Recruiting |
NCT05171374 -
pRospective Evaluation of Clinical Outcomes in Patients With metAsTatIŃ melanOma Treated With dabrafeNib and trAmetinib in reaL practicE
|
||
| Completed |
NCT03620019 -
Denosumab + PD-1 in Subjects With Stage III/ IV Melanoma
|
Phase 2 | |
| Recruiting |
NCT04562129 -
IL2 With Ipilimumab Followed by Nivolumab in Stage 3 or 4 Melanoma Patients
|
Phase 2 | |
| Recruiting |
NCT04990726 -
Immune Related Toxicity and Symptom Burden in Chronic Cancer Survivors With Melanoma Receiving Adjuvant Immunotherapy With Immune Checkpoint Inhibitors
|
||
| Recruiting |
NCT05970497 -
A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT05370807 -
A Clinical Trial of Regorafenib in Patients With Pretreated Advanced Melanoma
|
Phase 2 | |
| Recruiting |
NCT04045691 -
Binimetinib Plus Encorafenib Real Life Investigation of Next Generation Melanoma Treatment
|
||
| Not yet recruiting |
NCT05070221 -
Study of Oncolytic Virus in Combination With HX-008 and Axitinib in Melanoma Patients With Liver Metastasis
|
Phase 1 | |
| Not yet recruiting |
NCT05068453 -
Study of Oncolytic Virus in Combination With HX-008 and Radiotherapy in Melanoma Patients With Liver Metastasis
|
Phase 1 | |
| Recruiting |
NCT03353402 -
Fecal Microbiota Transplantation (FMT) in Metastatic Melanoma Patients Who Failed Immunotherapy
|
Phase 1 | |
| Recruiting |
NCT05598853 -
Intrathecal Double Checkpoint Inhibition
|
Phase 1 | |
| Recruiting |
NCT04521075 -
A Phase Ib Trial to Evaluate the Safety and Efficacy of FMT and Nivolumab in Subjects With Metastatic or Inoperable Melanoma, MSI-H, dMMR or NSCLC
|
Phase 1/Phase 2 | |
| Recruiting |
NCT06425926 -
Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors
|
Phase 1/Phase 2 | |
| Completed |
NCT03153085 -
A Study of Combination With TBI-1401(HF10) and Ipilimumab in Japanese Patients With Unresectable or Metastatic Melanoma
|
Phase 2 | |
| Recruiting |
NCT04741997 -
Adjuvant Therapy Based on Pathologic Response After Neoadjuvant Encorafenib Binimetinib in Melanoma
|
Early Phase 1 | |
| Recruiting |
NCT03991130 -
High Dose IL-2 in Combination With Anti-PD-1 to Overcome Anti-PD-1 Resistance in Metastatic Melanoma and Renal Cell Carcinoma
|
Phase 2 | |
| Active, not recruiting |
NCT04526899 -
Trial With BNT111 and Cemiplimab in Combination or as Single Agents in Patients With Anti-PD-1-refractory/Relapsed, Unresectable Stage III or IV Melanoma
|
Phase 2 | |
| Recruiting |
NCT06319196 -
Clear Me: Interception Trial to Detect and Clear Molecular Residual Disease in Patients With High-risk Melanoma
|
Phase 2 |